Repligen Corporation

NasdaqGS:RGEN Stock Report

Market Cap: US$8.4b

Repligen Past Earnings Performance

Past criteria checks 1/6

Repligen's earnings have been declining at an average annual rate of -33.2%, while the Life Sciences industry saw earnings growing at 0.6% annually. Revenues have been growing at an average rate of 6.5% per year. Repligen's return on equity is 0.08%, and it has net margins of 0.2%.

Key information

-33.18%

Earnings growth rate

-33.68%

EPS growth rate

Life Sciences Industry Growth21.51%
Revenue growth rate6.48%
Return on equity0.084%
Net Margin0.25%
Last Earnings Update30 Sep 2025

Recent past performance updates

Recent updates

Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Oct 31
Repligen Corporation Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Oct 04
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) 28% Share Price Surge

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Sep 01
Is Repligen (NASDAQ:RGEN) A Risky Investment?

Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S

Jul 29
Why Investors Shouldn't Be Surprised By Repligen Corporation's (NASDAQ:RGEN) P/S

Repligen: Long-Term Growth Gem Suffers Some Setbacks

Jun 08
User avatar

Biomanufacturing Expansion Will Create New Global Opportunities

Strong demand in biomanufacturing and effective market expansion are driving sustained revenue growth and improved margins for Repligen.

Repligen: Ongoing Bioprocessing Market Recovery

Mar 20

Is Repligen (NASDAQ:RGEN) A Risky Investment?

Feb 12
Is Repligen (NASDAQ:RGEN) A Risky Investment?

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 12

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Nov 08
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Repligen Stock: Still Quite Overvalued

May 30

Revenue & Expenses Breakdown

How Repligen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:RGEN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 25708226850
30 Jun 25674-1424447
31 Mar 25650-2324744
31 Dec 24634-2623843
30 Sep 24634-825841
30 Jun 24620923842
31 Mar 246202422242
31 Dec 236323621743
30 Sep 2365310121344
30 Jun 2371212421243
31 Mar 2376115421844
31 Dec 2280218621644
30 Sep 2280116621542
30 Jun 2277915920441
31 Mar 2273414619439
31 Dec 2167112818434
30 Sep 2159311916432
30 Jun 2150910014527
31 Mar 214338012723
31 Dec 203666011620
30 Sep 203274411219
30 Jun 203023110720
31 Mar 202862310021
31 Dec 19270219619
30 Sep 19253238117
30 Jun 19233277216
31 Mar 19210216916
31 Dec 18194176616
30 Sep 18184236416
30 Jun 18171236414
31 Mar 18155295810
31 Dec 1714128529
30 Sep 1712521438
30 Jun 1711318348
31 Mar 1711013318
31 Dec 1610512317
30 Sep 161007277
30 Jun 16968286
31 Mar 16888256
31 Dec 15849256
30 Sep 15789236
30 Jun 15748216
31 Mar 15687196
31 Dec 14648166

Quality Earnings: RGEN has a large one-off loss of $48.1M impacting its last 12 months of financial results to 30th September, 2025.

Growing Profit Margin: RGEN became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RGEN's earnings have declined by 33.2% per year over the past 5 years.

Accelerating Growth: RGEN has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: RGEN has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (-8.7%).

Return on Equity

High ROE: RGEN's Return on Equity (0.08%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/04 14:20
End of Day Share Price 2025/11/04 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Repligen Corporation is covered by 31 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Luke SergottBarclays
Robert WassermanBenchmark Company
Hugo SolvetBNP Paribas